ClinicalTrials.gg
Not yet recruitingNCT07542340Updated May 4, 2026

Effect of Osteopathic Intervention on Migraine

An interventional study of Osteopathic Intervention Protocol and Placebo technique in Migraine, sponsored by Escola Superior de Tecnologia da Saúde do Porto. Not yet recruiting. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2026-05-04.

Sponsored by Escola Superior de Tecnologia da Saúde do Porto · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Aug 2026, 3 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

Migraine is a common, disabling neurological condition characterized by severe, often unilateral pain accompanied by sensory symptoms like nausea and photophobia. Its pathophysiology involves activation of the trigeminovascular system, neuro-inflammation, and nervous system sensitisation.

Due to the convergence of trigeminal and cervical nerves in the upper neck (C2), manual therapy may influence migraine symptoms. Osteopathic techniques, such as suboccipital inhibition and C2 manipulation, aim to reduce pain intensity and frequency by normalising mobility and reducing nociceptive stimulation. While promising, further research is needed to validate these interventions through rigorous clinical trials.

Read the detailed description

Migraine is a frequent and disabling neurological pathology, characterised by crises of moderate to severe pain, often unilateral, and accompanied by sensory phenomena such as nausea, photophobia, and phonophobia. Its pathophysiology involves the activation of brainstem nuclei, Cortical Spreading Depression, and subsequent stimulation of the trigeminovascular system. The release of neuropeptides, such as Calcitonin Gene-Related Peptide (CGRP) and Substance P, triggers sterile neuro-inflammation and both peripheral and central sensitisation, contributing to the intensity and persistence of pain.

The connection between superior cervical structures and the trigeminovascular system, particularly at the C2 level, highlights the relevance of the cervicogenic region in modulating symptomatology. The convergence of trigeminal and cervical afferents in the trigeminocervical complex explains the possibility for manual interventions to influence the clinical parameters of migraine.

Osteopathic intervention has demonstrated potential in reducing the intensity, frequency, and duration of migraines. Notable techniques include the inhibition of the suboccipital muscles, which acts upon the high tension of this musculature associated with alterations in vertebrobasilar flow and nociceptive stimuli from the atlanto-occipital region; as well as the structural technique applied to the C2 vertebra, which seeks to normalise segmental mobility and reduce the stimulation of nociceptive pathways involved in migraine pathophysiology. Existing studies suggest symptomatic improvements following the application of these techniques, although gaps in evidence persist.

In light of these elements, investigation into the efficacy of applying an osteopathic protocol to migraine presents clinical and scientific relevance, justifying its application within the context of a clinical trial.

02

Conditions studied

  • Migraine

Browse trials for

Keywords

  • Suboccipital Inhibition
  • Migraine
  • Osteopathic Manipulative Treatment
  • Osteopathy
03

In context

Migraine Disorders

1,660 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

This study's planned enrollment of 45 is below the median of 80 across 1,271 interventional studies indexed under Migraine Disorders.

Browse Migraine Disorders studies →

Lead sponsor

Escola Superior de Tecnologia da Saúde do Porto is the lead sponsor of 39 studies on the registry; 20 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 50 years.
  • Presented five or more migraine episodes according to the criteria established by Monteiro et al. (2009), namely headache episodes with a minimum duration of 4 hours, unilateral location, pulsating character, photophobia, phonophobia, nausea, and vomiting.

Exclusion criteria

Exclusion Criteria:

  • recent traumas not investigated by complementary examinations, clinical history of cranio-cervical traumas, such as fracture, dislocation, and ligament rupture (Ricard \& Sallé, 2010; Croibier, 2005);
  • tumours, meningitis, neuropraxia, disc herniation, or cervical hemivertebra (Ricard \& Sallé, 2010; Croibier, 2005);
  • contagious disease, such as tuberculosis (Croibier, 2005);
  • cardiovascular diseases, such as severe arterial hypertension, venous thrombosis, myocardial infarction, angina pectoris, recent stroke, intracranial arterial aneurysm (Croibier, 2005);
  • advanced osteoporosis (Croibier, 2005);
  • radiotherapy/chemotherapy treatment currently active or within 6 months of the last session (Croibier, 2005);
  • anticoagulant medication, vitamin K, treatment with , analgesics, and NSAIDs 10 to 15 days per month (Bigal et al., 2008; Croibier, 2005; International Headache Society (IHS), 2018).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
45 participants (estimated)

Study arms

  • Placebo comparator
    Control group

    In the control group, bilateral contact of the acromioclavicular joint was performed.

    Other: Placebo technique

  • Experimental
    Experimental group

    The intervention consisted of two phases: a structural technique involving a high-velocity, low-amplitude thrust on segment C2 (Tixa \& Ebenegger, 2016), followed by a functional suboccipital inhibition technique (Chamtepie \& Pérot, 2008).

    Other: Osteopathic Intervention Protocol

Interventions

  • OtherOsteopathic Intervention Protocol

    Starting by locating the C2 segment with the metacarpophalangeal joint of the second finger, whilst the other hand rested on the participant's face, homolateral inclination and contralateral rotation were induced, applying a thrust directed into rotation. In this phase, two attempts were made on each side, starting with the right side. In the second phase, the suboccipital inhibition technique was performed in the occipital region, using contact with the thenar and hypothenar eminences, positioning the distal metacarpophalangeal joints at the level of the superior nuchal line, over the suboccipital musculature, promoting gentle pressure towards the ceiling, associated with cephalic traction, lasting for three minutes.

  • OtherPlacebo technique

    The researcher was positioned at the head of the table, making bilateral contact with the acromioclavicular joint and maintaining this position for 3 minutes, assisted by a stopwatch.

06

What researchers measure

Primary outcomes

  1. Headache Impact Test

    It consists of six questions, scored from 1 to 5, evaluating the frequency with which headache interferes with daily activities.

    Time frame: Two weeks after the third intervention

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Chantepie, A., & Pérot, J. F. (2008). Osteopatia clínica e prática. Andrei.
  • Bigal ME, Serrano D, Buse D, Scher A, Stewart WF, Lipton RB. Acute migraine medications and evolution from episodic to chronic migraine: a longitudinal population-based study. Headache. 2008 Sep;48(8):1157-68. doi: 10.1111/j.1526-4610.2008.01217.x. PubMed 18808500 ↗
  • Croibier.A, (2005). Diagnostic ostéopathique général. Elsevier SAS
  • Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018 Jan;38(1):1-211. doi: 10.1177/0333102417738202. No abstract available. PubMed 29368949 ↗
  • Tixa, S., & Ebenegger, B. (2016). Atlas de techniques articulaires ostéopathiques: Rachis cervical, thoracique, lombal et côtes (2ª ed.). Elsevier.
  • Rowlands, E., & Pozun, A. (2023). Osteopathic Manipulative Treatment: Suboccipital Release. Em StatPearls. StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK582126/
  • Ricard, F., Sallé, J. (2010). Tratado de osteopatía (3ª ed.). Panamericana.
  • Monteiro.J, Ribeiro.C, Luzeiro.I, Machado.M, Esperança.P, (2009). Recomendações terapêuticas para cefaleias (2.ª ed.). Sociedade Portuguesa de Neurologia & Sociedade Portuguesa de Cefaleias. 9(2).
  • Munoz-Gomez E, Ingles M, Serra-Ano P, Espi-Lopez GV. Effectiveness of a manual therapy protocol based on articulatory techniques in migraine patients. A randomized controlled trial. Musculoskelet Sci Pract. 2021 Aug;54:102386. doi: 10.1016/j.msksp.2021.102386. Epub 2021 Apr 30. PubMed 33989990 ↗
  • Link AS, Kuris A, Edvinsson L. Treatment of migraine attacks based on the interaction with the trigemino-cerebrovascular system. J Headache Pain. 2008 Feb;9(1):5-12. doi: 10.1007/s10194-008-0011-4. Epub 2008 Jan 23. PubMed 18217201 ↗
  • Machado, J., Barros, J., & Palmeira, M. (2006). Enxaqueca: fisiopatogenia, clínica e tratamento. Revista Portuguesa de Medicina Geral e Familiar, 22(4), 461-470.
  • Khan J, Asoom LIA, Sunni AA, Rafique N, Latif R, Saif SA, Almandil NB, Almohazey D, AbdulAzeez S, Borgio JF. Genetics, pathophysiology, diagnosis, treatment, management, and prevention of migraine. Biomed Pharmacother. 2021 Jul;139:111557. doi: 10.1016/j.biopha.2021.111557. Epub 2021 May 17. PubMed 34243621 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jun 2026; primary completion for Aug 2026, 2 months later.

Of 310 non-industry interventional studies with no phase under Migraine Disorders, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's planned 2 months is below that.

Counting every sponsor, half of 360 studies reached it within 15 months; a quarter within 7 and three quarters within 33.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2026
First posted
Apr 21, 2026
StartEst.
Jun 2026
Primary completionEst.
Aug 2026
CompletionEst.
Sep 2026
Last update
May 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 4, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07542340
Lead sponsor
Escola Superior de Tecnologia da Saúde do Porto
Responsible party
Natália Maria Oliveira Campelo (Doctor teacher, Escola Superior de Tecnologia da Saúde do Porto) — Principal investigator
First posted
Apr 21, 2026
Start date
Jun 2026 (estimated)
Primary completion
Aug 2026 (estimated)
Completion
Sep 2026 (estimated)
Last update
May 4, 2026

Study contacts

Natália MO Campelo, PhD
Contact
nmc@ess.ipp.pt
+351 222 061 000
Natália MO Campelo
principal investigator · ESS

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion